3-[2-(4-methoxyphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione | 1067647-14-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[2-(4-methoxyphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione
• 英文别名: 3-[2,5-dihydro-1-(4-methoxyphenyl)-3-methyl-5-oxo-1H-pyrazol-4-yl]-1-phenyl-3,5,6,7-tetrahydro-6,6-dimethyl-3-trifluoromethyl-1H-indole-2,4-dione；3-[2-(4-methoxyphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione
• CAS: 1067647-14-6
• 化学式: C₂₈H₂₆F₃N₃O₄
• 分子量: 525.527
• InChiKey: HRALEUPTUFQWEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  38
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  79
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-[1,5-dihydro-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazol-4-ylidene]-3,3,3-trifluoro-propanoic acid methyl ester 、 3-苯胺基-5,5-二甲基环己-2-烯-1-酮 以 氯仿 为溶剂， 反应 14.0h， 生成 3-[2-(4-methoxyphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione
  参考文献：
  名称：

  Synthesis and Evaluation of a Novel Indoledione Class of Long Chain Fatty Acid Elongase 6 (ELOVL6) Inhibitors

  摘要：

  Novel indoledione derivatives were synthesized and evaluated as long chain fatty acid elongase 6 (ELOVL6) inhibitors. Systematic optimization of an indole class of lead 1 led to the identification of potent ELOVL6 selective inhibitors. Representative inhibitor 37 showed sustained plasma exposure and good liver penetrability in mice. After oral administration, 37 potently inhibited ELOVL6 activity in the liver in mice.

  DOI：

  10.1021/jm900391x

文献信息

• INDOLEDIONE DERIVATIVE
  申请人：MSD K.K.

  公开号：EP2145884B1

  公开（公告）日：2014-08-06
• US8106086B2
  申请人：——

  公开号：US8106086B2

  公开（公告）日：2012-01-31
• [EN] COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR MODULER LE MÉTABOLISME DES LIPIDES
  申请人：[en]1BASE PHARMACEUTICALS, LLC

  公开号：WO2022212568A1

  公开（公告）日：2022-10-06

  The present disclosure features methods and related compositions that, inter alia, modulate the mitochondrial lipid shunt pathway, including the modulating the cellular mechanisms by which lipids (e.g., fatty acids) are transported between the mitochondria, stress granules, and lipid droplets.